Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 10 ... which has produced many of the industry's scientific leaders. Desmond-Hellmann guided Genentech's R&D successes and was recently named chancellor of UCSF. Byers has pioneered venture ...
2009 NOV 23 ... 3% and a specific activity of 2.2 +/- 0.2 Ci/mu mol," wrote H.S. Gill and colleagues, Genentech, Inc. The researchers concluded: "F-18-trastuzumab-ThioFab retained the ...
2009 NOV 16 ... for use in stomach cancer. Herceptin is marketed in the United States by Genentech, in Japan by Chugai and internationally by Roche. Since 1998, Herceptin has been used to ...
2009 NOV 23 ... the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The ...
2009 NOV 17 ... package, and wines from some of the world's top vineyards. Corporate sponsors include Genentech, Roche, Merrill Lynch, and Morgan Stanley, among others. All proceeds from ...
2009 NOV 16 ... partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several biotech companies and academic institutions. ...
2009 NOV 16 ... partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several biotech companies and academic institutions. ...
2009 NOV 16 ... dependence on ALK-mediated cell survival signaling," wrote E. Lin and colleagues, Genentech, Inc. The researchers concluded: "Collectively, these findings show the ...
2009 NOV 16 ... subsidiary of PDL, certain rights under its non-exclusive license agreements with Genentech, Inc., a wholly-owned subsidiary of Roche Holding, Ltd., including the right to receive ...
2009 NOV 23 ... large employers and employer coalitions. Executives from Bayer, Boehringer Ingelheim, Genentech, Novartis, Novo Nordisk and others contributed metrics, challenges and insights. ...
2009 NOV 16 ... Four AGMs were infused with 50 mg/kg of body weight anti-CD20 (rituximab; a gift from Genentech) every 21 days, starting from day -7 postinfection up to 184 days. The remaining AGMs ...
2009 NOV 26 ... strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the ...
2009 NOV 16 ... 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake ...
2009 NOV 16 ... earlier this year. • Carol Garvey, CCDM, director, CDM at Genentech, Inc. Garvey has been in the biotechnology industry for 25 years, including ...
2009 NOV 16 ... a GDC-0449-resistant mouse model of medulloblastoma," wrote R.L. Yauch and colleagues, Genentech, Inc. The researchers concluded: "These findings show that acquired ...
2009 NOV 16 ... exposures with MabThera have been recorded worldwide since its launch. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets MabThera in ...
2009 NOV 16 ... companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, ...
2009 NOV 16 ... Prior to VIVUS, Mr. Tam held various research and clinical development positions at Genentech from 1991 through 1993 and XOMA Corporation from 1987 to 1991. Mr. Tam received a B.S. ...
